Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

VTX958 versus placebo para el tratamiento de la psoriasis moderada a grave (Serenity PsO)

29 de octubre de 2026 actualizado por: Ventyx Biosciences, Inc

Estudio de fase 2, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y la seguridad de VTX958 en participantes con psoriasis de moderada a grave

This is a study to understand if taking VTX958 is safe and effective in participants diagnosed with moderate to severe psoriasis (PsO). Approximately 200 patients will take VTX958 Dose A, VTX958 Dose B, VTX958 Dose C, VTX958 Dose D, or placebo.

The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 16-week double-blind period (a participant receives active Dose A, Dose B, Dose C, Dose D, or placebo), a 16-week Long Term Extension (LTE) period, a 36-week Open Label Extension (OLE) period and a 4-week Follow-Up Period. The maximal duration of treatment will be approximately 16 months.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

222

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Fredericton, Canadá
        • Local Site # 124012
      • Mississauga, Canadá
        • Local Site # 124010
      • Montreal, Canadá
        • Local Site # 124002
      • North Bay, Canadá
        • Local Site # 124004
      • Oshawa, Canadá
        • Local Site # 124011
      • Peterborough, Canadá
        • Local Site # 124007
      • Québec, Canadá
        • Local Site # 124008
      • Toronto, Canadá
        • Local Site # 124005
      • Windsor, Canadá
        • Local Site # 124006
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35205
        • Local Site # 840012
      • Birmingham, Alabama, Estados Unidos, 35244
        • Local Site # 840006
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85032
        • Local Site # 840028
    • Arkansas
      • Bryant, Arkansas, Estados Unidos, 72022
        • Local Site # 840032
      • North Little Rock, Arkansas, Estados Unidos, 72117
        • Local Site # 840041
    • California
      • Fountain Valley, California, Estados Unidos, 92708
        • Local Site # 840031
      • Lomita, California, Estados Unidos, 90717
        • Local Site # 840026
      • Santa Rosa, California, Estados Unidos, 95405
        • Local Site # 840019
      • Sherman Oaks, California, Estados Unidos, 91403
        • Local Site # 840003
    • Florida
      • Boca Raton, Florida, Estados Unidos, 33486
        • Local Site # 840040
      • Doral, Florida, Estados Unidos, 33122
        • Local Site # 840011
      • Hialeah, Florida, Estados Unidos, 33012
        • Local Site # 840023
      • Miami Lakes, Florida, Estados Unidos, 33104
        • Local Site # 840021
      • North Miami Beach, Florida, Estados Unidos, 33162
        • Local Site # 840044
      • Ocala, Florida, Estados Unidos, 34470
        • Local Site # 840010
      • Tampa, Florida, Estados Unidos, 33607
        • Local Site # 840004
      • Tampa, Florida, Estados Unidos, 33613
        • Local Site # 840001
      • West Palm Beach, Florida, Estados Unidos, 33406
        • Local Site # 840045
    • Georgia
      • Marietta, Georgia, Estados Unidos, 30060
        • Local Site # 840029
    • Indiana
      • Clarksville, Indiana, Estados Unidos, 47129
        • Local Site # 840035
      • Indianapolis, Indiana, Estados Unidos, 46250
        • Local Site # 840005
      • Plainfield, Indiana, Estados Unidos, 46168
        • Local Site # 840030
    • Kentucky
      • Louisville, Kentucky, Estados Unidos, 40241
        • Local Site # 840013
    • Maryland
      • Rockville, Maryland, Estados Unidos, 20850
        • Local Site # 840022
    • Massachusetts
      • Brighton, Massachusetts, Estados Unidos, 02135
        • Local Site # 840008
    • Michigan
      • Bay City, Michigan, Estados Unidos, 48706
        • Local Site # 840016
      • Fort Gratiot, Michigan, Estados Unidos, 48059
        • Local Site # 840007
      • Troy, Michigan, Estados Unidos, 48084
        • Local Site # 840002
    • Minnesota
      • New Brighton, Minnesota, Estados Unidos, 55112
        • Local Site # 840034
    • Missouri
      • Saint Joseph, Missouri, Estados Unidos, 64506
        • Local Site # 840024
    • New Hampshire
      • Portsmouth, New Hampshire, Estados Unidos, 03801
        • Local Site # 840027
    • North Carolina
      • Wilmington, North Carolina, Estados Unidos, 28405
        • Local Site # 840042
    • Ohio
      • Mason, Ohio, Estados Unidos, 45040
        • Local Site # 840037
    • Oregon
      • Portland, Oregon, Estados Unidos, 97223
        • Local Site # 840009
    • South Dakota
      • Rapid City, South Dakota, Estados Unidos, 57702
        • Local Site # 840038
    • Tennessee
      • Murfreesboro, Tennessee, Estados Unidos, 37130
        • Local Site # 840015
    • Texas
      • Pflugerville, Texas, Estados Unidos, 78660
        • Local Site # 840039
    • Washington
      • Spokane, Washington, Estados Unidos, 99202
        • Local Site # 840014
      • Bialystok, Polonia
        • Local Site # 616015
      • Bialystok, Polonia
        • Local Site # 616016
      • Katowice, Polonia
        • Local Site # 616001
      • Krakow, Polonia
        • Local Site # 616014
      • Lodz, Polonia
        • Local Site # 616004
      • Lublin, Polonia
        • Local Site #616010
      • Mikołów, Polonia
        • Local Site # 616011
      • Nowa Sól, Polonia
        • Local Site # 616009
      • Ostrowiec Świętokrzyski, Polonia
        • Local Site # 616003
      • Poznan, Polonia
        • Local Site # 616008
      • Szczecin, Polonia
        • Local Site # 616007
      • Szczecin, Polonia
        • Local Site # 616013
      • Warsaw, Polonia
        • Local Site # 616005
      • Wroclaw, Polonia
        • Local Site # 616002
      • Wroclaw, Polonia
        • Local Site # 616006
      • Wroclaw, Polonia
        • Local Site # 616018

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Male or female participant aged 18 years or older.
  • History of primarily plaque psoriasis for at least 6 months prior to the screening visit.
  • Has had stable psoriasis conditions for at least 3 months before screening.
  • Has moderate to severe plaque psoriasis as defined by a PASI score of ≥ 12 and an sPGA score of ≥ 3 at screening and Day 1.
  • Has plaque psoriasis covering ≥ 10% of the total BSA at screening and Day 1.
  • Deemed by the investigator to be eligible for phototherapy or systemic therapy.
  • Females of childbearing potential must agree to use a highly effective contraceptive method from at least 4 weeks prior to Day 1 until at least 4 weeks after the last dose of study product.

Exclusion Criteria:

  • Female who is breastfeeding, pregnant, lactating, or who is planning to become pregnant during the study.
  • Has evidence of erythrodermic, pustular, predominantly inverse or guttate psoriasis, or drug-induced psoriasis.
  • History of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.
  • Participant is known to have immune deficiency or is immunocompromised.
  • Has immune-mediated conditions commonly associated with psoriasis, such as psoriatic arthritis, active uveitis, inflammatory bowel disease, that currently require systemic treatment (including corticosteroids, immunosuppressants, or biologics).

Note: Participants with immune-mediated conditions commonly associated with psoriasis that do not require systemic treatment may be included in the study.

  • Has used any topical medication that could affect psoriasis (including corticosteroids, retinoids, vitamin D analogues [such as calcipotriol], Janus kinase [JAK] inhibitors, or tar) within 2 weeks prior to Day 1.
  • Has used any systemic treatment that could affect psoriasis (including corticosteroids, oral retinoids, immunosuppressive medication, anakinra, methotrexate, cyclosporine, oral JAK inhibitors, or apremilast) within 4 weeks prior to Day 1.

Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed.

  • Participant has received any ultraviolet B (UVB) phototherapy (including tanning beds) or excimer laser within 4 weeks prior to Day 1.
  • Participant has had psoralen and ultraviolet A (PUVA) treatment within 4 weeks prior to Day 1.
  • Participant has received treatment with an investigational or marketed TYK2 inhibitor.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: VTX958 300 mg BID (Placebo Controlled)

Participants received one 300 milligram (mg) VTX958 tablet administered orally twice daily (BID) to maintain the blind in Period 1.

VTX958 administered orally

Experimental: VTX958 225 mg BID (PC)

Participants received one 225 mg VTX958 tablet administered orally BID to maintain the blind in Period 1.

VTX958 administered orally

Experimental: VTX958 300 mg QD (PC)

Participants received 300 mg VTX958 tablet administered orally once daily (QD), and matching placebo tablets administered orally QD to maintain the blind in Period 1.

VTX958 administered orally

Experimental: VTX958 50 mg BID (PC)

Participants received 50 mg VTX958 tablet administered orally BID and matching placebo tablets administered orally BID to maintain the blind in Period 1.

VTX958 administered orally

Comparador de placebos: Placebo BID (PC)

Participants received placebo tablets matched to VTX958, administered BID to maintain the blind in Period 1.

Placebo administered orally

Experimental: Long Term Extension Period (LTE): VTX958 300 mg BID

Participants who received 300 mg VTX958 dose administered orally BID in Period 2.

VTX958 administered orally

Experimental: LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID

Participants who received 225 mg VTX958 at Period 1 continued to receive 225 mg VTX958 dose administered orally BID in Period 2.

VTX958 administered orally

Experimental: LTE: VTX958 300 mg QD (PC)/ VTX958 300 mg QD

Participants who received 300 mg VTX958 at Period 1 continued to receive 300 mg VTX958 dose administered orally QD in Period 2.

VTX958 administered orally

Experimental: LTE: VTX958 50 mg BID (PC)/ VTX958 50 mg BID

Participants who received 50 mg VTX958 at Period 1 continued to receive 50 mg VTX958 dose administered orally BID in Period 2.

VTX958 administered orally

Experimental: Open Label Extension (OLE): VTX958 300 mg BID

Participants who received 300 mg VTX958 dose administered orally BID in Period 3.

VTX958 administered orally

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Period 1: Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 16
Periodo de tiempo: Week 16

Participants achieving a ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI) score (PASI 75) at Week 16 were considered responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

As pre-specified in the statistical analysis plan this analysis was planned to compare each VTX958 dose with Placebo.

Week 16
Period 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Observed During the Study of VTX958
Periodo de tiempo: Baseline up to week 16

The number of participants with TEAEs and SAEs observed during the study of VTX958.

A TEAE is any condition that was not present prior to treatment with the study product but appeared following treatment, was present at treatment initiation but worsened during treatment, or was present at treatment initiation but resolved and then reappeared while the individual was on treatment (regardless of the intensity of the AE when the treatment was initiated).

An SAE or reaction is any untoward medical occurrence that, at any dose has any of the following consequences:

  • Results in death
  • Is life-threatening
  • Requires in-patient hospitalization or prolongation of existing hospitalization
  • Results in persistent or significant disability/incapacity
  • Is a congenital anomaly/birth defect
Baseline up to week 16

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Period 1: Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) Score of 0 (Clear) or 1 (Almost Clear) With ≥2 Grade Improvement From Baseline at Week 16
Periodo de tiempo: Week 16

Percentage of participants achieving a sPGA score of 0 (clear) or 1 (almost clear) with ≥2-grade improvement from baseline at Week 16. The investigator assessed psoriasis severity on a 5-point scale from 0 (clear) to 4 (severe):

0 = Clear: No signs of psoriasis; post-inflammatory hyperpigmentation may occur

  1. = Almost clear: Normal to pink lesions; no thickening; no or minimal focal scaling
  2. = Mild: Pink to light red color; slight thickening; mainly fine scaling
  3. = Moderate: Dull bright red erythema; moderate thickening; moderate scaling
  4. = Severe: Bright to deep red; severe thickening with hard edges; coarse scaling covering most or all lesions
Week 16
Period 1: Change From Baseline in PASI Score at Week 16
Periodo de tiempo: Baseline, Week 16

Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects.

The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

Baseline, Week 16
Period 1: Percent Change From Baseline in PASI Score at Week 16
Periodo de tiempo: Baseline, Week 16

Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects.

The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

Baseline, Week 16
Percentage of Participants Achieving ≥90% Reduction From Baseline in PASI-90 at Week 16
Periodo de tiempo: Week 16

Percentage of participants achieving ≥90% reduction from baseline in PASI-90 at Week 16. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

Week 16
Period 1: Percentage of Participants Achieving ≥100% Reduction From Baseline in PASI-100 at Week 16
Periodo de tiempo: Week 16

Percentage of participants achieving ≥100% reduction from baseline in PASI-100 at Week 16. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

Week 16
Period 1: Change From Baseline in Dermatology Life Quality Index (DLQI) at 16 Weeks
Periodo de tiempo: Baseline, Week 16

The DLQI is a simple 10-question validated questionnaire where, except for question 7, each question is rated from 0 (Not at all) to 3 (Very much). If question 7 is answered 'yes', this question is assigned a score of 3. If question 7 is answered 'No' or 'Not Relevant', this question is assigned a score 0, except if either 'a lot' or 'a little' is ticked. If so, this question is assigned a score of 2 or 1, respectively. Then, the DLQI total score is the sum of the 10 questions and ranges from 0 to 30, where higher scores indicate worst disease severity.

Baseline, Week 16
Period 1: Change From Baseline in the Percentage of Body Surface Area (BSA) Affected at Week 16
Periodo de tiempo: Baseline, Week 16

Least square mean was determined with MMRM using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, prior biologic treatment for psoriasis (Yes/No), and baseline score as a covariate, with participant as a random effect baseline is the last non-missing pre-dose value.

BSA is a measurement of the affected skin area. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). The overall BSA affected by psoriasis plaques is estimated based on the palm area of the participant hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total BSA. Negative change from baseline indicates improvement.

Baseline, Week 16

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Snehal Naik, PhD, Ventyx Biosciences, Inc

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

17 de noviembre de 2022

Finalización primaria (Actual)

25 de septiembre de 2023

Finalización del estudio (Actual)

20 de diciembre de 2023

Fechas de registro del estudio

Enviado por primera vez

2 de diciembre de 2022

Primero enviado que cumplió con los criterios de control de calidad

8 de diciembre de 2022

Publicado por primera vez (Actual)

19 de diciembre de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

19 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

29 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • VTX958-201
  • 2022-002887-59 (Número EudraCT)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .